Intellia Therapeutics (NTLA) announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units for an aggregate of 30,600 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis
- Intellia Therapeutics price target raised to $7 from $4 at Baird’
- Intellia Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Citizens says nex-z return to clinic should add ‘significant value’ to Intellia
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!